Vitara Pancreas

Treatment decisions guided by tumor biology.

Vitara is powered by Valar Labs’ AI pathology platform, designed to help physicians and patients make personalized, evidence-based decisions about cancer treatments.

Explore the TechnologyRequest Information
Vitara Pancreas
Physician reviewing test results

Replace guesswork in first-line treatment for advanced pancreatic cancer.

Precision care in advanced pancreatic cancer.
Treatment Selection

A better chance at first-line treatment benefit.

Choose a front-line chemotherapy regimen based on tumor biology for better clinical outcomes.

Patients had superior PFS and OS when treated with the regimen matched to their biomarker results¹

G Preference: Gemcitabine + nab-Paclitaxel
F Preference: FOLFIRINOX
Developed and validated in patients from over 50 centers, including those from multiple prospective studies.¹
Fast results in 2–3 days from receipt of existing specimen, with no additional procedures required and no consumption of tissue.
VITARA PORTFOLIO

Vitara is Valar Labs’ GI-focused portfolio of AI-powered pathology tests, designed to guide personalized care decisions.

Our Computational Histology Artificial Intelligence (CHAI) platform uses standard pathology slides to purpose-build biomarkers that solve real clinical challenges. Results are delivered in days, not weeks, for informed, efficient care.

VITARA TECHNOLOGY

Built on Biology.

Novel Biomarkers

Valar Labs’ research team has developed and validated multiple unique Vitara biomarker signatures with data from thousands of patients with pancreatic cancer using histology features.

Expertly Trained AI

Valar Labs’ board-certified pathologists created 500,000+ annotations of tumors and their microenvironment to train our Computational Histology Artificial Intelligence (CHAI) platform, grounding the technology in biology.

Fast, H&E-Based Testing

Leveraging existing tumor specimens, first-of-its-kind AI analyzes H&E pathology slides and returns actionable results in days for timely treatment decisions.

Are you a:

Patient
Patient

Understand how your tumor’s biology can help guide the best first-line treatment choice for your advanced pancreatic cancer.

Learn more
Healthcare Professional
Healthcare Professional

Access objective, AI-driven biomarker data to support informed treatment decisions and move beyond arbitrary first-line selection in advanced pancreatic cancer.

Get in touch
Industry Partner
Industry Partner

Explore collaboration opportunities to bring precision oncology tools to more patients and advance the standard of care in gastrointestinal cancers.

Work with us

Frequently asked questions about Vitara

What is Vitara Pancreas ChemoPredict?

Vitara Pancreas ChemoPredict is an AI-powered diagnostic test that analyzes histologic features of the tumor and its microenvironment to classify regimen preference (G-Preference or F-Preference) and guide first-line treatment selection in advanced pancreatic cancer.

How does the test work?

The test uses a digitized H&E-stained slide from the diagnostic biopsy. Our AI model, built on the proprietary CHAI platform, analyzes morphologic features to determine whether the tumor shows a preference for gemcitabine-based or 5-FU-based first-line chemotherapy.

What specimen types are accepted?

The test accepts core or fine needle biopsy (FNB) specimens from the pancreas or liver. It is indicated for patients with advanced or metastatic first-line pancreatic ductal adenocarcinoma (PDAC).

How long does it take to get results?

Expect results within 2–3 days of sample receipt. The fast turnaround ensures results are available to inform treatment decisions without causing delays in starting therapy.

Does the test consume additional tissue?

No. Testing uses a digitized image of the existing H&E-stained slide from the diagnostic biopsy, preserving the tissue block for additional molecular testing or clinical needs.

What is the clinical evidence behind the test?

In the pivotal study (Hendifar, Knox et al, Journal of Clinical Oncology, 2026), biomarker-treatment alignment was associated with superior PFS and OS. The test was developed and validated across over 50 centers, including data from multiple prospective studies.

What do G-Preference and F-Preference mean?

G-Preference indicates the tumor’s histologic features are associated with better outcomes on gemcitabine-based chemotherapy (e.g., Gemcitabine/nab-paclitaxel). F-Preference indicates a predicted benefit from 5-FU-based regimens (e.g., FOLFIRINOX). These classifications help guide treatment alignment.

How do I order the test?

Contact our team at support@valarlabs.com for more information.

Peer-Reviewed Research

See the Evidence

Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer

February 2026

Computational histology artificial intelligence (CHAI) predicts benefit of first-line chemotherapy regimen in advanced pancreatic ductal adenocarcinoma (PDAC)

January 2026

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

April 2023

Ready for Vitara?

Join leading physicians using Vitara computational histology biomarkers to guide personalized care in advanced pancreatic cancer.

Get in touch

1. Hendifar (Knox) et al. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer. Journal of Clinical Oncology. February 11, 2026. Real-world progression-free survival (rwPFS) defined as time to next treatment or death (TNTD).